Periodic Reporting for period 1 - ALADDIN (Accelerated Discovery Nanobody Platform)

Since the approval of the first monoclonal antibody (mAb) 30 years ago, therapeutic mAbs and Ab-derived molecules have come to dominate the biologics market. Currently, +160 mAbs are in clinical use for different diseases, out of which nearly 100 target cancer. Global market...